Prof Michael Boyer speaks to ecancer about the phase III KEYNOTE-598 study that he presented at the WCLC 2020 meeting.

He explains that KEYNOTE-598 compared the use pembrolizumab with ipilimumab or placebo in patients with non-small cell lung cancer and PD-L1 tumour proportion scores of ≥50%.

Prof Boyer reports that no difference was seen in terms of efficacy of the treatments however an increase in adverse events was seen with the addition of ipilimumab.